<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35068000</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1468-3083</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>36</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the European Academy of Dermatology and Venereology : JEADV</Title>
          <ISOAbbreviation>J Eur Acad Dermatol Venereol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Frontal fibrosing alopecia in breast cancer patients on aromatase-inhibitor: 2 cases.</ArticleTitle>
        <Pagination>
          <StartPage>e470</StartPage>
          <EndPage>e472</EndPage>
          <MedlinePgn>e470-e472</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jdv.17958</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Murad</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0001-7435-6200</Identifier>
            <AffiliationInfo>
              <Affiliation>Departments of Dermatology and Histopathology, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Our Lady of Lordes, Drogheda, Ireland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>UCD School of Medicine, Dublin, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wolinska</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Our Lady of Lordes, Drogheda, Ireland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bergfeld</LastName>
            <ForeName>W F</ForeName>
            <Initials>WF</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Dermatology and Histopathology, Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Eur Acad Dermatol Venereol</MedlineTA>
        <NlmUniqueID>9216037</NlmUniqueID>
        <ISSNLinking>0926-9959</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047072">Aromatase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.1</RegistryNumber>
          <NameOfSubstance UI="D001141">Aromatase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000505" MajorTopicYN="N">Alopecia</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001141" MajorTopicYN="N">Aromatase</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047072" MajorTopicYN="N">Aromatase Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008010" MajorTopicYN="Y">Lichen Planus</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>24</Day>
          <Hour>5</Hour>
          <Minute>50</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35068000</ArticleId>
        <ArticleId IdType="doi">10.1111/jdv.17958</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997; 109: 296-300.</Citation>
        </Reference>
        <Reference>
          <Citation>Murad A, Bergfeld W. 5-alpha-reductase inhibitor treatment for frontal fibrosing alopecia: an evidence-based treatment update. J Eur Acad Dermatol Venereol 2018; 32: 1385-1390.</Citation>
        </Reference>
        <Reference>
          <Citation>Pindado-Ortega C, Saceda-Corralo D, Moreno-Arrones ÓM et al. Effectiveness of dutasteride in a large series of patients with frontal fibrosing alopecia in real clinical practice. J Am Acad Dermatol 2021; 84: 1285-1294.</Citation>
        </Reference>
        <Reference>
          <Citation>Murad A, Bergfeld WF. Reply to Effectiveness of dutasteride in a large series of patients with frontal fibrosing alopecia in real clinical practice. J Am Acad Dermatol 2021; 85: e93.</Citation>
        </Reference>
        <Reference>
          <Citation>Ladizinski B, Bazakas A, Selim MA, Olsen EA. Frontal fibrosing alopecia: a retrospective review of 19 patients seen at Duke University. J Am Acad Dermatol 2013; 68: 749-755.</Citation>
        </Reference>
        <Reference>
          <Citation>Ho A, Shapiro J. Medical therapy for frontal fibrosing alopecia: A review and clinical approach. J Am Acad Dermatol 2019; 81: 568-580.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
